HR Execs on the Move

Intra-Cellular Therapies

www.intracellulartherapies.com

 
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Pete Morrison
District Manager, Neuroscience Sales Profile
Sanjeev Narula
Chief Financial Officer Profile

Similar Companies

Meier Clinics

Meier Clinics provides Christian counseling for those struggling with depression, anxiety, marriage issues, grief, ADD or ADHD, bipolar, and a variety of other issues.

Medefil Inc

Medefil Inc is a Glendale Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Talia Technology (Marco Ophthalmic)

Talia Technology (Marco Ophthalmic Inc.) is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Highland Therapeutics

Highland Therapeutics Inc., a Toronto-based specialty pharmaceutical company. It is a specialty pharmaceutical company leveraging its proprietary technologies to optimize the delivery of previously approved drug products.

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.